Financhill
Sell
22

ABOS Quote, Financials, Valuation and Earnings

Last price:
$1.38
Seasonality move :
-12.72%
Day range:
$1.36 - $1.42
52-week range:
$1.28 - $5.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.38x
Volume:
142.7K
Avg. volume:
291.6K
1-year change:
-58.43%
Market cap:
$82.9M
Revenue:
--
EPS (TTM):
-$1.38

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Upside
    No price target exists because of limited analyst coverage.
  • Price Target Downside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Acumen Pharmaceuticals has 682.61% upside to fair value with a price target of -- per share.

ABOS vs. S&P 500

  • Over the past 5 trading days, Acumen Pharmaceuticals has overperformed the S&P 500 by 0.68% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Acumen Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Acumen Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Acumen Pharmaceuticals reported revenues of --.

Earnings Growth

  • Acumen Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Acumen Pharmaceuticals reported earnings per share of -$0.50.
Enterprise value:
-89.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
1.33x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$39.4M -$56.9M -$92.9M -$16M -$32.3M
EBITDA -$39.3M -$47.5M -$77.9M -$12.9M -$28.7M
Diluted EPS -$0.95 -$1.12 -$1.38 -$0.24 -$0.50
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets -- $204.9M $202.6M $218.6M $207.6M
Total Assets -- $234.8M $203.3M $286.4M $267M
Current Liabilities -- $1.5M $6.6M $6.1M $19.9M
Total Liabilities -- $1.5M $6.6M $6.1M $49.8M
Total Equity -- $233.4M $196.7M $280.3M $217.2M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$27.6M -$46M -$67.3M -$12.9M -$24.6M
Cash From Investing $49.6M -$143.3M -$30.4M -$92M -$10.1M
Cash From Financing -- $126.8M $36.1M $122.8M -$42K
Free Cash Flow -$27.7M -$46M -$67.3M -$12.9M -$24.6M
ABOS
Sector
Market Cap
$82.9M
$44.2M
Price % of 52-Week High
27.11%
48.19%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.68%
1-Year Price Total Return
-58.43%
-35.43%
Beta (5-Year)
--
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $1.40
200-day SMA
Sell
Level $2.48
Bollinger Bands (100)
Sell
Level 1.63 - 2.65
Chaikin Money Flow
Buy
Level 4.4M
20-day SMA
Sell
Level $1.49
Relative Strength Index (RSI14)
Sell
Level 36.08
ADX Line
Sell
Level 23.04
Williams %R
Neutral
Level -70.943
50-day SMA
Sell
Level $1.70
MACD (12, 26)
Sell
Level -0.09
25-day Aroon Oscillator
Sell
Level -60
On Balance Volume
Neutral
Level 105.1M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Stock Forecast FAQ

In the current month, ABOS has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ABOS average analyst price target in the past 3 months is --.

  • Where Will Acumen Pharmaceuticals Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Acumen Pharmaceuticals share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About Acumen Pharmaceuticals?

    Analysts are divided on their view about Acumen Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Acumen Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.

  • What Is Acumen Pharmaceuticals's Price Target?

    The price target for Acumen Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is ABOS A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Acumen Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of ABOS?

    You can purchase shares of Acumen Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Acumen Pharmaceuticals shares.

  • What Is The Acumen Pharmaceuticals Share Price Today?

    Acumen Pharmaceuticals was last trading at $1.38 per share. This represents the most recent stock quote for Acumen Pharmaceuticals. Yesterday, Acumen Pharmaceuticals closed at $1.38 per share.

  • How To Buy Acumen Pharmaceuticals Stock Online?

    In order to purchase Acumen Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is SoFi Worth?
What Is SoFi Worth?

Since SoFi’s CEO began snapping up shares of the student…

Is CVX a Buy, Sell or Hold?
Is CVX a Buy, Sell or Hold?

Energy giant Chevron Corporation (NYSE:CVX) has long been a pure-play…

What Will NVIDIA Stock Be Worth in 2030?
What Will NVIDIA Stock Be Worth in 2030?

NVIDIA (NASDAQ:NVDA) has been by far one of the best…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Sell
17
CE alert for Feb 21

Celanese [CE] is down 4.21% over the past day.

Sell
22
GLBE alert for Feb 20

Global E Online [GLBE] is down 8.41% over the past day.

Buy
72
HIMS alert for Feb 20

Hims & Hers Health [HIMS] is down 3.39% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock